Immune response following intraocular delivery of recombinant viral vectors. - Wikidata - awgldk - TriplyDB

Immune response following intraocular delivery of recombinant viral vectors.

Immune response following intraocular delivery of recombinant viral vectors.

http://www.wikidata.org/entity/Q34198445

about

Cell Penetrating Peptide Conjugated Chitosan for Enhanced Delivery of Nucleic Acid An empty E1, E3, E4 adenovirus vector protects photoreceptors from light-induced degeneration Comparative study of the transfection efficiency of commonly used viral vectors in rhesus monkey (Macaca mulatta) brains Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice.Ocular localization and transduction by adenoviral vectors are serotype-dependent and can be modified by inclusion of RGD fiber modifications Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer.Vector platforms for gene therapy of inherited retinopathies.Lentiviral mediated gene delivery to the anterior chamber of rodent eyes Efficient gene delivery to photoreceptors using AAV2/rh10 and rescue of the Rho(-/-) mouse Gene therapy for proliferative ocular diseases.An HNF1α-regulated feedback circuit modulates hepatic fibrogenesis via the crosstalk between hepatocytes and hepatic stellate cells.Engineering a polymeric gene delivery vector based on poly(ethylenimine) and hyaluronic acid.Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients.The liberation of CD44 intracellular domain modulates adenoviral vector transgene expression.Retinal Gene Therapy: Current Progress and Future Prospects.Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor gene attenuates lung cancer growth.Let There Be Light: Gene and Cell Therapy for Blindness.Rescue of sight by gene therapy - closer than it may appear.Adenoviral gene transfer of bioactive TGFbeta1 to the rodent eye as a novel model for anterior subcapsular cataract Barriers for retinal gene therapy: separating fact from fiction.Effects of Acute Low-Dose Exposure to the Chlorinated Flame Retardant Dechlorane 602 and Th1 and Th2 Immune Responses in Adult Male Mice.Primate neural retina upregulates IL-6 and IL-10 in response to a herpes simplex vector suggesting the presence of a pro-/anti-inflammatory axis.Advances in gene therapy technologies to treat retinitis pigmentosa.Correction of Monogenic and Common Retinal Disorders with Gene Therapy.Novel gene therapeutic strategies for the induction of tolerance in cornea transplantation.Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies.Neovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals.Lentivirus delivery by adsorption to tissue engineering scaffolds.Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward.AT2R Gene Delivered by Condensed Polylysine Complexes Attenuates Lewis Lung Carcinoma after Intravenous Injection or Intratracheal Spray.Novel AAV serotypes for improved ocular gene transfer.Prospects for genetic modulation of corneal graft survival.Tropism of engineered and evolved recombinant AAV serotypes in the rd1 mouse and ex vivo primate retina.Gene Manipulation Strategies to Identify Molecular Regulators of Axon Regeneration in the Central Nervous System.CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10.Gene expression changes induced by a recombinant E1-/E3- adenovirus type 5 vector in human mammary epithelial cells.Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses.Rapid, widespread transduction of the murine myocardium using self-complementary Adeno-associated virus In vitro adenovirus mediated gene transfer to the human cornea.Virology and immunology of gene therapy, or virology and immunology of high MOI infection with defective viruses.

P2860

Q26774462-72519FD8-EECD-453E-8195-5DFA23DE3EC3 Q33574612-5E50D8F8-3B05-488A-9160-A97047034D40 Q33577391-E7DEED42-F3E2-43D9-B608-F8B1CCFB0D54 Q33739804-1EC2F81B-D0CC-4A00-944D-736E07B74931 Q34215308-334EC0F6-F8A5-4FC5-B068-E38C04ACA69A Q34325086-87C7B81E-57BC-4EA8-9F88-76D218F394DC Q34561531-CA113F41-050F-4BE6-BB51-1F687D3086C2 Q35153670-F338DEEF-0D2B-4BA0-B9E6-3DC97549C066 Q35651062-AF753218-C158-4AD3-99FC-4B08DFA48E40 Q35842653-057B9B64-EB71-4839-98E9-521B88CEA377 Q35925605-CC66FA1E-3D9B-48E6-A2E6-93C597EAD5DF Q35957338-F74092E4-A260-47F0-8554-1B5CF7116FE2 Q36147481-6542B1AF-06CB-4263-BD41-57466B83E075 Q36294870-364B9255-1E09-4B76-9E38-B9152B636F87 Q36306263-ED6EBA36-C648-463D-9A2F-7815B4630AF3 Q36594271-BCDE566E-E291-4618-9BB9-1B8025539411 Q36654534-E5071BE8-E7FD-4898-8051-0EBB9EFB95EC Q36951825-E3334A49-E10F-40DF-B594-935A976D2176 Q37109133-72B7A589-539E-4D62-A6D9-6C50426C9CEA Q37195446-41E96953-4661-4B60-A0E1-4135875777C1 Q37230329-DAB71700-FC59-444F-8F37-525E13C96959 Q37331180-BD737325-768D-47FC-82EC-F2C9CFD60F9F Q37427526-C2E32998-9DD1-4ADE-9543-D2DA2E1C4A02 Q37676230-E202507C-749F-44E4-8755-18DEA4B46EF6 Q37755334-3FC2E5DE-F17C-4BDA-9E33-9ECD0F8B959A Q37784661-EDB2F0D0-39D9-4A2B-8371-011B7E831816 Q37882685-AF2C37F9-E3D6-4A9A-A12A-49AAD5BB6C47 Q38349634-4FDBF1B5-4ABC-4227-80DF-4011AB0CDD2A Q38732888-79C04B72-6D07-4E76-8E21-1A32D1BD4449 Q38814333-6B0A7556-588C-439B-8668-6AAC10927DC8 Q39708886-7B819F73-08C5-4BB5-B1C0-C534092D3E37 Q40016839-607BDD5E-2504-4023-A948-BF736946059D Q40057668-1684BC45-E171-4D45-A640-D75005680035 Q40077177-EA2D7C8E-A21A-4717-AE6C-8098CB5FEF5C Q40369908-2D3A2FC5-33DF-4C34-84CD-2CEFED7C1C87 Q40396580-7131169B-C3B7-4D1D-9045-B2017A0A2273 Q40413612-673912AD-DD2F-4CB2-BE45-17BCF4BDC0E2 Q41909668-9DDDC83E-B16A-4D66-93BF-31E95E28D334 Q42907140-56968EF3-871A-4AEC-AD8A-FDD863BF0A07 Q45862358-2B3F5818-1D25-4C8F-AC02-C1352B343442

P2860

Immune response following intraocular delivery of recombinant viral vectors.

http://www.wikidata.org/entity/Q34198445

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Immune response following intraocular delivery of recombinant viral vectors.

@ast

Immune response following intraocular delivery of recombinant viral vectors.

@en

Immune response following intraocular delivery of recombinant viral vectors.

@nl

type

label

Immune response following intraocular delivery of recombinant viral vectors.

@ast

Immune response following intraocular delivery of recombinant viral vectors.

@en

Immune response following intraocular delivery of recombinant viral vectors.

@nl

prefLabel

Immune response following intraocular delivery of recombinant viral vectors.

@ast

Immune response following intraocular delivery of recombinant viral vectors.

@en

Immune response following intraocular delivery of recombinant viral vectors.

@nl

P1433

Q34198445-3C9DD1ED-EB97-4A0F-8D82-C2C658FA3E9C

P1476

Q34198445-E4CBD77A-A78F-480B-8B51-40C61F414902

P2093

Q34198445-3BB288D5-06D1-4D4F-A6D0-0BA0F2A6E625

P2860

Q34198445-0AC4492F-BFAA-4E5A-B82E-30FF954740DF

Q34198445-0F694A92-9AEC-4456-83DC-1A0D15F3ED30

Q34198445-1A6EBAE6-C304-4264-A70A-CACD04138EA5

Q34198445-1E9B07A8-FB62-45BD-9370-FB4963A57C0E

Q34198445-1E9ED1B1-EF9C-4A07-B1E1-631383D95526

Q34198445-1EA4BCA7-234F-4F40-BAE6-BB46D13031F4

Q34198445-1EFD6DC9-B3F1-485B-B468-43BB590A1364

Q34198445-352F8528-2C6B-4379-BA27-AC02F0F0E3F4

Q34198445-3E20F595-8E74-4DB3-91CC-81A29C656AAB

Q34198445-3F9FD5CC-DE2F-4163-A684-31450105CF99

P2888

Q34198445-71830C24-0581-4698-8A74-12F5FB1D5240

P304

Q34198445-F754A098-EF09-455A-B279-DC4DF4DE3C2C

P31

Q34198445-7BED0464-B811-4393-901C-15591027764A

P356

Q34198445-BF9B0E56-409F-4B6E-8A22-1CC952277EE2

P433

Q34198445-7FFA77AB-84FA-49E5-BEFF-B136BFA9B95F

P478

Q34198445-CAAF0CD9-BB9E-4A0D-BC9D-2AF5E85F9027

P577

Q34198445-FAFB38B4-4F62-4695-ADFE-0A1F9D7BD14E

P5875

Q34198445-6E844CF0-10CB-4590-8868-AE8AA237AA8E

P698

Q34198445-63B60FB7-8EE0-46A6-A976-86EA6E6892CA

P356

P1433

P1476

Immune response following intraocular delivery of recombinant viral vectors.

@en

P2093

Bennett J

http://www.w3.org/2001/XMLSchema#string

P2860

Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy

Suicide gene therapy for treatment of retinoblastoma in a murine model.

Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Müller cells temporarily rescues injured retinal ganglion cells.

Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus.

Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina.

Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.

Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa.

Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy.

Long-term protection of retinal structure but not function using RAAV.CNTF in animal models of retinitis pigmentosa.

Gene replacement therapy in the retinal degeneration slow (rds) mouse: the effect on retinal degeneration following partial transduction of the retina.

P2888

P304

977-982

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.GT.3302030

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10752558

http://www.w3.org/2001/XMLSchema#string

P698

12756418

http://www.w3.org/2001/XMLSchema#string